-
diaDexus (San Francisco) has received FDA clearance for a new automated version of its PLAC Test.
-
The American Heart Association (AHA; Dallas) recently reported that U.S. deaths from heart disease and stroke dropped about 25% from 1999 to 2005, five years ahead of goals.
-
The most common way to investigate the functions of miRNAs is to inhibit them one at a time.
-
Cardiva Medical; ev3; LifeSync; NewCardio; Stereotaxis
-
CryoLife's (Kennesaw, Georgia) decellularized replacement heart valve used to replace diseased, damaged, malformed or malfunctioning pulmonary valves in early February received FDA 510(k) clearance. Children who face multiple surgeries for congenital heart defects will likely be the most significant beneficiaries of the new valves, according to the company, by potentially reducing the number of surgeries they must have over a lifetime.
-
FDA has asked for more information and clarification regarding a pre-market approval application for the ATS 3f aortic bioprosthesis from ATS Medical (Minneapolis), a company that makes products for cardiac surgery.
-
According to a paper published in the American Heart Journal (2008; Vol. 155, Issue 1: 128-132), the Bio-Engineered R stent from OrbusNeich (Hong Kong), is feasible and safe for use in acute myocardial infarction (AMI).
-
-
The second-generation of drug-eluting stent (DES) technology is now reality in the U.S. Medtronic (Minneapolis) in early February reported FDA approval of the Endeavor DES, making it the first in the DES 2.0 family of these devices to win marketing okay in the U.S.
-
Cytori Therapeutics (San Diego) reported enrollment of the first two patients in a clinical trial using adipose-derived stem and regenerative cells in the treatment of heart attack using its device/cell treatment combination system.
